Research Center of Neurology, Moscow, Russia.
Vavilov Institute of General Genetics, Russian Academy of Sciences, Moscow, Russia.
Bull Exp Biol Med. 2024 Jun;177(2):225-230. doi: 10.1007/s10517-024-06161-5. Epub 2024 Aug 2.
Data on the participation of microbiota in the development of Parkinson's disease allow us to discuss the ability of bacterial preparations to influence the processes leading to neurodegeneration. We studied the effect of oral administration of Limosilactobacillus fermentum U-21 lyophilisate on a model of Parkinson's disease in rats induced by combined intranigral injection of LPS and systemic administration of paraquat. The toxins significantly increased the number of missteps in the "narrowing beam walking" test, but a tendency to a decrease in this parameter was shown after treatment with U-21. It should be noted that U-21 did not reduce the neuronal death in the substantia nigra, but mitigated the inflammatory glial response, decreased the accumulation of phosphorylated α-synuclein and complement protein C3. Our study demonstrated the efficiency of the combined model of parkinsonism and reduction of proinflammatory changes under the influence of pharmabiotic without changes in the nigral neuronal death and motor deficits.
有关微生物群参与帕金森病发展的数据使我们能够讨论细菌制剂影响导致神经退行性变的过程的能力。我们研究了口服发酵乳杆菌 U-21 冻干制剂对 LPS 联合脑内注射和百草枯全身给药诱导的帕金森病大鼠模型的影响。毒素显著增加了“狭窄光束行走”试验中的失误次数，但在用 U-21 治疗后，该参数显示出下降的趋势。值得注意的是，U-21 并未减少黑质中的神经元死亡，但减轻了炎症性神经胶质反应，减少了磷酸化α-突触核蛋白和补体蛋白 C3 的积累。我们的研究表明，在不改变黑质神经元死亡和运动缺陷的情况下，益生菌的联合帕金森病模型和促炎变化减少的效果。
